The main purpose of this study is to evaluate the safety of LY3041658 in healthy participants, including first generation Japanese. The study will also investigate how the drug is processed and affects key immune cells. Study participation will last 4 months. Protocol amended in January, 2016 to include first generation Japanese participants.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
54
Administered SC
Administered as slow IV infusion
Administered as slow IV infusion
Parexel Early Phase Unit at Glendale
Glendale, California, United States
PAREXEL-Phase 1 Baltimore Harbor Hospital Center
Baltimore, Maryland, United States
The Number of Participants with One or More Drug-Related Adverse Events
Time frame: Baseline to study completion (Day 85)
Pharmacokinetics: Maximum Plasma Concentration (Cmax) of LY3041658
Time frame: Predose through Day 85, at specified timepoints
Pharmacokinetics: Area Under the Plasma Concentration-time Curve (AUC) from Time 0 to Time of Last Measurable Concentration (tlast)
Time frame: Predose through Day 85, at specified timepoints
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.